Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study.

Background: Increased mineralocorticoid activity is one of the plausible causes of chronic central serous chorioretinopathy (CSCR) and mineralocorticoid inhibitors such as eplerenone have been investigated as its potential therapy. This study investigates the short-term safety and efficacy of oral eplerenone in patients with chronic CSCR.

Patients And Methods: Prospective study of 13 eyes of 13 patients with the diagnosis of chronic CSCR.